Moleculin Biotech, Inc. MBRX 深 滬
已收盤 05-08 16:00:00 美东时间
2.47
-0.020
-0.80%
華盛通- 最 高2.55
- 今 開2.5074
- 成交量 64.68万股
- 最 低 2.35
- 昨 收 2.49
- 總市值 1318.09万
- 52周最高 25.00
- 市盈率 靜 --
- 換手率 12.12%
- 52周最低 1.79
- 委 比 18.19%
- 總股本 533.64万
- 歷史最高 21555.00
- 量 比 9.99
- 振 幅 8.03%
- 歷史最低 1.79
- 每 手 1
- 風險率 6.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Moleculin Biotech Announces Significant Advancement In IP Portfolio With Issuance Of Hong Kong Patent Covering Proprietary Method Of Reconstituting Liposomal Annamycin
Solid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data ReleaseHOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today
05-08 20:47
Moleculin Highlights Promising Preclinical Data for L-ANN
Moleculin Biotech ( ($MBRX) ) has shared an announcement. On April 23, 2026, Mo...
04-23 20:51
Moleculin to present annamycin cardiac safety pooled analysis at ASCO 2026
Moleculin to present annamycin cardiac safety pooled analysis at ASCO 2026 Moleculin Biotech disclosed acceptance of an abstract on its lead drug candidate annamycin for poster presentation at 2026 ASCO Annual Meeting. Data will be presented May 30, 2026, in Chicago. Poster reports pooled analysis i
04-21 20:36
Moleculin Biotech Stockholders Approve Warrant Share Issuance
Moleculin Biotech ( ($MBRX) ) has shared an update. At a special meeting of sto...
04-15 23:59
Scalable Biotech Manufacturing Unlocks a $14B Market
Issued on behalf of Avaí Bio, Inc. VANCOUVER, BC, March 27, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary — The global cell therapy manufacturing market is hitting a pivotal inflecti...
03-27 21:15
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
Moleculin Biotech reports FY results
Moleculin Biotech press release (MBRX): FY EPS of -$28.42. As of December 31, 2025, the Company had cash and cash equivalents of $8.9 million and prepaid expenses and other current assets of $0.8 mill...
03-20 02:59
Moleculin Biotech Q4 EPS $(26.06) Misses $(11.60) Estimate
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(26.06) per share which missed the analyst consensus estimate of $(11.60) by 124.75 percent. This is a 181.73 percent decrease over losses of $(9.25) per
03-19 21:38
Moleculin Biotech Updates Investors with New Corporate Presentation
Moleculin Biotech ( ($MBRX) ) just unveiled an update. On March 19, 2026, Molec...
03-19 21:28
Moleculin Biotech Inc reports results for the quarter ended December 31 - Earnings Summary
Moleculin Biotech Inc reports results for the quarter ended December 31 - Earnings Summary Moleculin Biotech Inc MBRX.OQ reported quarterly adjusted earnings of $13.04 per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-9.32. The
03-19 19:59
